Design Therapeutics (NASDAQ:DSGN) outlined progress across three clinical-stage programs and discussed upcoming catalysts during an Oppenheimer healthcare conference presentation led by CEO Pratik ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results